Evidence map›Paper›PMID 40877317›Full record

ArticleNature communications2025

Molecular basis of potent antiviral HLA-C-restricted CD8

Yoshihiko Goto, You Min Ahn, Mako Toyoda, Hiroshi Hamana, Yan Jin, Yoshiki Aritsu, Takeshi Nakama, Yuka Tajima, Janesha C Maddumage, Huanyu Li and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Yoshihiko Goto *Division of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
You Min Ahn *Immunity and Infection program, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Bundoora, VIC, 3086, Australia.ORCID http://orcid.org/0000-0002-9008-9867
Mako ToyodaDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Hiroshi HamanaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, 9300194, Japan.
Yan JinDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Yoshiki AritsuDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Takeshi NakamaDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Yuka TajimaDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Janesha C MaddumageImmunity and Infection program, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Bundoora, VIC, 3086, Australia.
Huanyu LiDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.
Mizuki KitamatsuDepartment of Applied Chemistry, Faculty of Science and Engineering, Kindai University, Osaka, 577-8502, Japan.
Hiroyuki KishiDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, 9300194, Japan.ORCID http://orcid.org/0000-0002-8740-5371
Akiko YonekawaCenter for the Study of Global Infection, Kyushu University Hospital, Kyushu University, Fukuoka, 8128582, Japan.
Dhilshan JayasingheImmunity and Infection program, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Bundoora, VIC, 3086, Australia.
Nobuyuki ShimonoCenter for the Study of Global Infection, Kyushu University Hospital, Kyushu University, Fukuoka, 8128582, Japan.
Yoji NagasakiDivision of Infectious Diseases, Clinical Research Institute, National Hospitalization Organization, Kyushu Medical Center, Fukuoka, 8108563, Japan.
Rumi MinamiInternal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, 8108563, Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, 1138677, Japan.
Noritaka SekiyaDepartment of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, 1138677, Japan.ORCID http://orcid.org/0000-0002-0765-4221
Yusuke TomitaDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, 8608556, Japan.
Demetra S M ChatzileontiadouImmunity and Infection program, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Bundoora, VIC, 3086, Australia.
Hirotomo NakataDepartment of Hematology, Rheumatology and Infectious Diseases, Kumamoto University School of Medicine, Kumamoto University Hospital, Kumamoto, 8608556, Japan.
So NakagawaDepartment of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa, 2591193, Japan.ORCID http://orcid.org/0000-0003-1760-3839
Takuro SakagamiDepartment of Respiratory Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, 8608556, Japan.
Takamasa UenoDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan.ORCID http://orcid.org/0000-0003-4852-4236
Stephanie GrasImmunity and Infection program, La Trobe Institute for Molecular Science (LIMS), La Trobe University, Bundoora, VIC, 3086, Australia. S.Gras@latrobe.edu.au.ORCID http://orcid.org/0000-0001-7416-038X
Chihiro MotozonoDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto, 8600811, Japan. motozono@kumamoto-u.ac.jp.ORCID http://orcid.org/0000-0002-9027-742X

Funding

Department of Health | National Health and Medical Research Council (NHMRC) #034677Department of Health | National Health and Medical Research Council (NHMRC) #1159272Japan Agency for Medical Research and Development (AMED) 20fk0108451s0101Japan Agency for Medical Research and Development (AMED) 21fk0410046Japan Agency for Medical Research and Development (AMED) 23wm0325064MEXT | Japan Society for the Promotion of Science (JSPS) 19H03703MEXT | Japan Society for the Promotion of Science (JSPS) 22H02877MEXT | Japan Society for the Promotion of Science (JSPS) 22H03119MEXT | Japan Society for the Promotion of Science (JSPS) 22K07089MEXT | Japan Society for the Promotion of Science (JSPS) 22KK0277
6 · The paper itself

Abstract

The emergence of SARS-CoV-2 Variants of Concern (VOC) is a major clinical threat; however, VOC remain susceptible to cytotoxic T lymphocyte (CTL) recognition. Therefore, it is crucial to identify potent CTL responses targeting conserved epitopes across VOCs. Here, we demonstrate that the nucleocapsid (N) protein induces efficient CTL responses in early pandemic COVID-19 convalescent donors. In the context of the HLA-A24-B52-C12 haplotype, prevalent in Japan, the KF9 peptide (N

Indexed as

CD8-Positive T-LymphocytesCoronavirus Nucleocapsid ProteinsCOVID-19Epitopes, T-LymphocyteHLA-C AntigensImmunodominant EpitopesSARS-CoV-2HumansPhosphoproteinsT-Lymphocytes, CytotoxicVirus ReplicationCoronavirus Nucleocapsid ProteinsEpitopes, T-LymphocyteHLA-C AntigensImmunodominant Epitopesnucleocapsid phosphoprotein, SARS-CoV-2Phosphoproteins

Identifiers

PMID40877317
PMCPMC12394707

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.